Pfiz­er's Lor­bre­na bests Xalko­ri in PhI­II read­out — is it a po­ten­tial suc­ces­sor?

Pfiz­er has long pinned hopes on lor­la­tinib as be­ing a suc­ces­sor to Xalko­ri for ALK-pos­i­tive non-small cell lung can­cer, and the phar­ma re­leased da­ta Wednes­day in­di­cat­ing that may even­tu­al­ly be the case.

Lor­la­tinib, now mar­ket­ed as Lor­bre­na, met its pri­ma­ry end­point in a Phase III tri­al by show­ing a sig­nif­i­cant­ly im­proved pro­gres­sion-free sur­vival as com­pared to Xalko­ri in pa­tients who had pre­vi­ous­ly not re­ceived any treat­ment for their ill­ness. Lor­bre­na had al­ready been ap­proved as a sec­ond-line treat­ment for ALK-pos­i­tive metasta­t­ic NSCLC back in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER